Benzene Ring Containing Patents (Class 564/265)
  • Patent number: 10638755
    Abstract: Suggested is a antimicrobial agent An antimicrobial composition comprising (a) at least one acetophenone derivative of formula (I) in which R1 stands for hydrogen or methyl, and R2 stands for hydrogen, hydroxyl or a —OCH3 group, or a cosmetically or pharmaceutically acceptable salt thereof, and (b) at least one second antimicrobial agent.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: May 5, 2020
    Assignee: Symrise AG
    Inventors: Manuel Pesaro, Bernd Hölscher, Gerhard Schmaus, Antje Köhler
  • Patent number: 10093621
    Abstract: The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is —COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, straight or branched C1-C10 alkyl, aryl, or R2CO— wherein R2 is straight or branched C1-C10 alkyl, for use as antitumoral agents.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 9, 2018
    Assignee: FONDAZIONE IRCCS INSTITUTO NAZIONALE DEI TUMORI
    Inventors: Maria Grazia Daidone, Valentina Appierto, Paola Tiberio, Sabrina Dallavalle, Loana Musso, Elisa Niccolini
  • Patent number: 9035053
    Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: May 19, 2015
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
  • Patent number: 9029592
    Abstract: The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: May 12, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Keith R. Fandrick, Joe Ju Gao, Jason Alan Mulder, Nitinchandra D. Patel, Xingzhong Zeng
  • Publication number: 20150045213
    Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
    Type: Application
    Filed: March 6, 2013
    Publication date: February 12, 2015
    Inventors: Anthony Cornelis O'Sullivan, Olivier Loiseleur, Roman Staiger, Torsten Luksch, Thomas Pitterna
  • Publication number: 20150018566
    Abstract: The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene.
    Type: Application
    Filed: August 27, 2012
    Publication date: January 15, 2015
    Inventors: John Jarlath Walsh, Richard Shah, Emmet Martin McCormack, Gillian Joy Hudson, Martina White, Gary Daniel Stack, Brian William Moran, Adrian Coogan, Elaine Carmel Breen
  • Patent number: 8912214
    Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: December 16, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
  • Publication number: 20140303255
    Abstract: Provided are compounds and compositions thereof that are useful as antioxidants in personal care formulations. The compounds are of the formula I: wherein R, R1, R2, R3, R4, R5 and R6 are as defined herein.
    Type: Application
    Filed: November 6, 2012
    Publication date: October 9, 2014
    Inventors: Mrunalini S. Dhamdhere, George D. Green, Shao-Ching Hung, Raymond J. Swedo
  • Publication number: 20140200350
    Abstract: There are provided compounds comprising optionally substituted (FORMULA I) fused with one or two optionally substituted (FORMULA II), wherein A and E each independently represent —CH2—, —NH—, —O—, —S—, or —C(?O)— and B represents a bond, —CH2—, —NH—, —O—, —S—, or —C(?O)—, said compound having directly or indirectly attached thereto at least one acyl and/or oxime ester group. Such compounds are useful inter alias as photoinitiators.
    Type: Application
    Filed: May 24, 2012
    Publication date: July 17, 2014
    Applicant: AMERICAN DYE SOURCE, INC.
    Inventors: My T. Nguyen, Jean-Philippe Tremblay-Morin, Philippe Gaudreault
  • Publication number: 20140116292
    Abstract: The present invention relates to a cellulose acetate film used for optical compensation and a retardation enhancer used therein, and relates to a cellulose acetate film which has a high retardation value in the thickness direction (Rth).
    Type: Application
    Filed: June 20, 2012
    Publication date: May 1, 2014
    Applicant: SK INNOVATION CO., LTD.
    Inventors: Won Yeob Kim, Min Joung Im, Seung Eon Lee, Myoung Lae Kim, Yong Gyun Cho, Sang Yeup Lee, Ki Yup Kim
  • Publication number: 20130217674
    Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
    Type: Application
    Filed: August 22, 2011
    Publication date: August 22, 2013
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
  • Publication number: 20130211130
    Abstract: The present invention relates to a process of making a compound of formula (I): Wherein, R1, R2, R4 and X are as defined herein.
    Type: Application
    Filed: February 7, 2013
    Publication date: August 15, 2013
    Applicant: Boehringer Ingelheim International Gmbh
    Inventors: Keith R. FANDRICK, Joe Ju GAO, Jason Alan MULDER, Nitinchandra D. PATEL, Xingzhong ZENG
  • Publication number: 20130204008
    Abstract: The present invention provides novel methods for synthesizing PPAR? sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.
    Type: Application
    Filed: August 9, 2011
    Publication date: August 8, 2013
    Applicant: Metabolic Solutions Development Company, LLC
    Inventors: Steven P. Tanis, Timothy Parker, Robert C. Gadwood, Gerald D. Artman, III, James R. Zeller
  • Publication number: 20130184292
    Abstract: The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: wherein the variables are as defined herein.
    Type: Application
    Filed: September 28, 2012
    Publication date: July 18, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, John Studley, Francoise Yvonne Theodora Marie Pierard, Steven John Durrant, Benjamin Joseph Littler, Robert Michael Hughes, David Andrew Siesel, Paul Angell, Armando Urbina, Yi Shi
  • Publication number: 20130184494
    Abstract: According to the first embodiment of the present invention, an oxide of a hydrocarbon compound can be produced with high yield and high productivity by oxidizing the hydrocarbon compound with molecular oxygen in the co-presence of an N-hydroxy compound, such as methyl ethyl ketone or N-hydroxysuccinimide, and a phosphate ester, such as dibutyl phosphate. According to another embodiment of the present invention, an oxide of a hydrocarbon compound can be produced with high yield by using an oxidation catalyst that comprises an oxime compound, such as methyl ethyl ketone. According to another embodiment of the present invention, an alcohol and/or a ketone can be produced with high yield by oxidizing the hydrocarbon compound at a temperature of 160° C. or less, and by decomposing the resulting hydroperoxide, for example, in a unit having an inner surface formed by a material from which no transition metal ion is generated.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 18, 2013
    Applicant: USE Industries, Ltd.
    Inventors: Kazunori Kurosawa, Joji Funatsu, Naoya Katagiri, Junichi Kugimoto
  • Publication number: 20130109718
    Abstract: This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.
    Type: Application
    Filed: October 24, 2012
    Publication date: May 2, 2013
    Applicant: Hoffmann-La Roche Inc.
    Inventor: Hoffmann-La Roche Inc.
  • Publication number: 20130072721
    Abstract: A method for producing a nitrone of formula (I) wherein R is a branched alkyl group having from four to thirty carbon atoms; R1, R2, R3 and R4 independently are hydrogen or alkyl groups having from one to six carbon atoms from an imine having formula (II)
    Type: Application
    Filed: November 9, 2012
    Publication date: March 21, 2013
    Applicant: ROHM AND HAAS COMPANY
    Inventor: Rohm and Haas Company
  • Publication number: 20130018140
    Abstract: The invention relates to N-bridged polynitrons and their use for cross-linking of unsaturated polymers, as well as a curable composition comprising (a) a N-bridged polynitron, (b) an unsaturated polymer or a mixture of polymers, wherein at least one unsaturated polymer contains unsaturated functions or functional groups which can react with the polynitron, (c) optionally fillers, (d) optionally pigments, (e) optionally additives such as plasticizers, stabilizers, photoinitiators, and (f) optionally, other cross-linking agents such as polyisocyanates, bisdienes, polyoxaziridines, and their use as adhesives, rubber, filling, sprayable thick-layer filler, ink, paint, powder paint, waterborne paint or solvent based paint. Further, the invention relates to cross-linking products obtainable by curing the curable composition according to the present invention.
    Type: Application
    Filed: December 21, 2010
    Publication date: January 17, 2013
    Inventors: Marcus Dickmeis, Hakan Cinar, Helmut Ritter
  • Publication number: 20120283101
    Abstract: The present invention pertains to plant additives containing a molecule selected in a family of compounds, wherein said molecule can modulate some molecular markers and physiological modifications observed in cases of phosphate deficiency. The family of compounds comprises the molecule MC2 of formula (I) as well as analogues thereof.
    Type: Application
    Filed: September 17, 2010
    Publication date: November 8, 2012
    Inventors: Mathilde Clement, Thierry Desnos, Laurent Nussaume
  • Publication number: 20120220769
    Abstract: A process for preparing 7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidin-5-amine, intermediates useful in that process, and processes for preparing said intermediates are disclosed.
    Type: Application
    Filed: August 3, 2010
    Publication date: August 30, 2012
    Applicant: Schering Corporation
    Inventors: Shen-Chun Kuo, Yonggang Chen, Jeffrey M. Eckert, William W. Leong, Nanfei Zou, Gabriel C. Kuklis
  • Publication number: 20110288251
    Abstract: The invention relates to novel O-dialkylamino-isoureas and polymerizable compositions comprising these O-dialkylamino-isoureas of compounds of the general formula (I). The invention further relates to the use of O-dialkylamino-isoureas as polymerization initiators, especially to prepare coatings or for controlled degradation of polyolefins.
    Type: Application
    Filed: December 28, 2009
    Publication date: November 24, 2011
    Applicant: BASF SE
    Inventors: Peter Nesvadba, Lucienne Bugnon Folger, Antoine Carroy, Marc Faller
  • Publication number: 20110263567
    Abstract: The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO/VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.
    Type: Application
    Filed: September 11, 2009
    Publication date: October 27, 2011
    Applicant: Semmelweis Egyetem
    Inventors: Péter Mátyus, Kálmán Magyar, Marjo Pihlavisto, Klára Gyires, Norbert Haider, Yinghua Wang, Patrick Woda, Petra Dunkel, Éva Tóth-Sarudy, Gÿorgy Túrós
  • Patent number: 8013187
    Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-? or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-? or PDE4.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: September 6, 2011
    Assignee: Amorepacific Corporation
    Inventors: Yeonjoon Kim, Sun-Young Kim, Jung Sun Hwang, Kyoung Min Lim, Miyoung Park, Hyun Ju Koh, Sa-Yong Hong, Song Seok Shin, Jin Kyu Choi, Joo-Hyun Moh, Shin Chung, Byoung Young Woo, Sung Il Kim
  • Patent number: 7951607
    Abstract: The present invention provides methods and compositions for detecting, identifying and measuring the abundance of chemical nerve agents. Methods and compositions of the present invention are capable of providing selective detection of phosphorous based nerve agents, such as nerve agents that are esters of methyl phosphonic acid derivatives incorporating a moderately good leaving group at the phosphorus. Selectivity in the present invention is provided by a sensor composition having an alpha (?) effect nucleophile group that undergoes specific nucleophilic substitution and rearrangement reactions with phosphorus based nerve agents having a tetrahederal phosphorous bound to oxygen. The present invention includes embodiments employing a sensor composition further comprising a reporter group covalently linked to the alpha effect nucleophile group allowing rapid optical readout of nerve agent detection events, including direct visual readout and optical readout via spectroscopic analysis.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: May 31, 2011
    Assignee: University of Wyoming
    Inventors: Robert C. Corcoran, Aaron D. Strickland
  • Publication number: 20100210524
    Abstract: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, wherein W, X, Y, Z, R1, R2, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are as defined in the specification. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity.
    Type: Application
    Filed: July 21, 2008
    Publication date: August 19, 2010
    Inventors: Theresa Apelqvist, Joakim Löfstedt, Thomas Norin, Mattias Wennerstål, Xiongyu Wu, Lars Hagberg
  • Publication number: 20100130784
    Abstract: Substituted 1,1,1-trifluoro-3-[(benzyl)-(pyrimidin-2-yl)-amino]-propan-2-ol compounds, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
    Type: Application
    Filed: February 13, 2006
    Publication date: May 27, 2010
    Inventors: George Chang, Michael Patrick Pence
  • Publication number: 20100130757
    Abstract: The present invention provides methods and compositions for detecting, identifying and measuring the abundance of chemical nerve agents. Methods and compositions of the present invention are capable of providing selective detection of phosphorous based nerve agents, such as nerve agents that are esters of methyl phosphonic acid derivatives incorporating a moderately good leaving group at the phosphorus. Selectivity in the present invention is provided by a sensor composition having an alpha (?) effect nucleophile group that undergoes specific nucleophilic substitution and rearrangement reactions with phosphorus based nerve agents having a tetrahederal phosphorous bound to oxygen. The present invention includes embodiments employing a sensor composition further comprising a reporter group covalently linked to the alpha effect nucleophile group allowing rapid optical readout of nerve agent detection events, including direct visual readout and optical readout via spectroscopic analysis.
    Type: Application
    Filed: January 21, 2010
    Publication date: May 27, 2010
    Applicant: UNIVERSITY OF WYOMING
    Inventors: Robert C. Corcoran, Aaron D. Strickland
  • Publication number: 20100069423
    Abstract: Described herein are Chk2-inhibitor compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Application
    Filed: July 27, 2006
    Publication date: March 18, 2010
    Applicant: Government of the US, as represented by the Secretary, Department of Health and Human Services
    Inventors: Yves Pommier, Robert H. Shoemaker, Dominic Scudiero, Michael Currens, John Cardellina, Andrew Jobson
  • Patent number: 7674788
    Abstract: The invention relates to new pteridines which are suitable for treating respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system and cancers. This invention also relates to pharmaceutical compositions containing these compounds.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: March 9, 2010
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Horst Dollinger, Domnic Martyres, Juergen Mack, Rolf Goeggel, Birgit Jung, Peter Nickolaus
  • Publication number: 20100029588
    Abstract: The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or their habitat.
    Type: Application
    Filed: March 8, 2008
    Publication date: February 4, 2010
    Applicant: BAYER CROPSCIENCE AG
    Inventors: Thomas Seitz, Klaus Kunz, Wahed Ahmed Moradi, Jörg Nico Greul, Darren James Mansfield, Urlich Heinemann, Amos Mattes, Oswald Ort, Jean-Pierre Vors, Peter Dahem, Ulrike Wachendorff-Neumann, Arnd Voerste
  • Patent number: 7608738
    Abstract: The present invention relates to a process for the coammoximation, that is to say for the simultaneous ammoximation, of ketones, in particular of cyclic ketones such as cyclododecanone and cyclohexanone. Ammoximation is taken to mean here the preparation of oximes from ketones or aldehydes together with hydrogen peroxide and ammonia and in the presence of a catalyst which essentially consists of silicon, titanium and oxygen, for example titanium silicalite.
    Type: Grant
    Filed: August 2, 2004
    Date of Patent: October 27, 2009
    Assignee: Degussa AG
    Inventors: Juergen Herwig, Martin Roos, Georg Oenbrink, Bernd Guenzel, Dirk Kuppert
  • Publication number: 20090227572
    Abstract: The present invention provides methods of enhancing healing of wound associated with diabetes, comprising administering an effective amount of one or more of certain hydroxylamine derivatives to a subject in need thereof. In another aspect, the instant invention provides methods of treating or preventing peripheral nervous system neuropathies. Peripheral nervous system neuropathies may but need not be diabetic neuropathies, and may but need not be associated with a diabetic wound. The invention also provides pharmaceutical compositions comprising a certain hydroxylamine derivative or a pharmaceutically acceptable salt thereof, optionally in combination with one or more additional therapeutic agents. In certain compositions and methods, the additional therapeutic agent is a second hydroxylamine derivative or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 17, 2009
    Publication date: September 10, 2009
    Applicant: Cytrx Corporation
    Inventors: Jack R. Barber, Shi Chung Ng
  • Patent number: 7560597
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2?,4?-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as “DCBP compounds”), and more particularly to compounds selected from compounds of the following formula and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: n is independently 1, 2, 3, or 4; W is independently —C(?O)—, —CH(OH)—, or —C(?NOROX)—; ROX is independently —H or C1-3alkyl; J is independently: —H, —RE1, —C(?O)—RE2, —C(?O)—O—RE3, —C(?O)—O—S(?O)2ORE4, —C(?O)—(CH2)n—C(?O)ORE5, —C(?O)—(CH2)n—NRNE1RNE2, —C(?O)—(CH2)n—NRNE3—C(?O)RE6, —C(?O)—(CH2)n—C(?O)—NRNE4RNE5, or —P(?O)(ORE7)(ORE8); wherein each of RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is independently: —H, C1-3alkyl, -Ph, or —CH2-Ph.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: July 14, 2009
    Assignee: The University Court of the University of Aberdeen
    Inventors: Iain Robert Greig, Robert Jurgen van 't Hof, Stuart Hamilton Ralston
  • Publication number: 20090054629
    Abstract: Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.
    Type: Application
    Filed: February 8, 2006
    Publication date: February 26, 2009
    Applicant: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Jeffery W. Kelly, Steven M. Johnson, H. Michael Petrassi
  • Publication number: 20090042957
    Abstract: The invention relates to compounds of the formula (I) in which A1, A2, R1, R2, R3, R4, R5 and Y are as defined in the description, to processes and intermediates for their preparation and to their use for controlling pests.
    Type: Application
    Filed: December 21, 2005
    Publication date: February 12, 2009
    Applicant: Bayer CropScience AG
    Inventors: Peter Jeschke, Michael Muller, Iris Escher, Michael E. Beck, Oliver Gaertzen, Olga Malsam, Karl-Josef Haack
  • Publication number: 20090036501
    Abstract: 2-cyclopenten-1-one oxime derivatives represented by Formula (I), or pharmaceutically acceptable salts thereof inhibit the production of TNF-? or PDE4, and therefore show therapeutic effect in inflammatory or immunological disorders mediated through TNF-? or PDE4.
    Type: Application
    Filed: November 30, 2005
    Publication date: February 5, 2009
    Applicant: AmorePacific Corporation
    Inventors: Yeonjoon Kim, Sun-Young Kim, Jung Sun Hwang, Kyoung Min Lim, Miyoung Park, Hyun Ju Koh, Sa-yong Hong, Song Seok Shin, Jin Kyu Choi, Joo Hyun Moh, Chin Chung, Byoung Young Woo, Sung II Kim
  • Patent number: 7476673
    Abstract: Compounds of the formula where the variables are as defined in the specification, are useful for preventing or treating emphysema and related pulmonary conditions of mammals and other diseases and conditions which are responsive to RAR? agonist retinoids, such as skin related diseases, including but not limited to acne and psoriasis.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Publication number: 20080221220
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain 2?,4?-dichloro-biphenyl-4-yl-hydroxy-ketones and related compounds (collectively referred to herein as “DCBP compounds”), and more particularly to compounds selected from compounds of the following formula and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: n is independently 1, 2, 3, or 4; W is independently —C(?O)—, —CH(OH)—, or —C(?NOROX)—; ROX is independently —H or C1-3alkyl; J is independently: —H, —RE1, —C(?O)—RE2, —C(?O)—O—RE3, —C(?O)—O—S(?O)2ORE4, —C(?O)—(CH2)n—C(?O)ORE5, —C(?O)—(CH2)n—NRNE1RNE2, —C(?O)—(CH2)n—NRNE3—C(?O)RE6, —C(?O)—(CH2)n—C(?O)—NRNE4RNE5, or —P(?O)(ORE7)(ORE8); wherein each of RE1, RE2, RE3, RE4, RE5, RE6, and RE7 is independently: —H, C1-3alkyl, -Ph, or —CH2-Ph.
    Type: Application
    Filed: March 6, 2008
    Publication date: September 11, 2008
    Inventors: Iain Robert Greig, Robert Jurgen van 't Hof, Stuart Hamilton Ralston
  • Patent number: 7399577
    Abstract: Compounds of the formula (I) or (II) wherein R1 is C1-C10haloalkylsulfonyl, halobenzenesulfonyl, C2- C10haloalkanoyl, halobenzoyl; R2 is halogen or C1-C10 haloalkyl; Arl is phenyl, biphenylyl, fluorenyl, naphthyl, anthracyl, phenanthryl, or heteroaryl, all of which are optionally substituted; Ar?1 is for example phenylene, naphthylene, diphonylene, heteroarylene, oxydiphenylene, phenyleneD-D1-D-phenylene or —Ar?1-A1—Y1-A1—Ar?1—; wherein these radicals optionally are substituted; Ae?, is phenylene, naphthylene, anthracylene, phenanthrylene, or heteroarylene, all optionally substituted; A, is for example a direct bond, —0—, —S—, or —NR6—; Y, inter alia is C1-C18alkylene; X is halogen; D is for example —0—, —S— or —NR6—; D, inter alia is C1-C18alkylene; are particularly suitable as photolatent acids in ArF resist technology.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: July 15, 2008
    Assignee: Ciba Specialty Chemicals Corporation
    Inventors: Hitoshi Yamato, Toshikage Asakura, Akira Matsumoto, Peter Murer, Tobias Hintermann
  • Patent number: 7312361
    Abstract: Bisaryloxime ethers and bisarylhydroazones are shown to be effective for inhibiting formation of amyloid fibrils of transthyretin.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: December 25, 2007
    Assignee: The Scripps Research Institute
    Inventors: Jeffery W. Kelly, Steven M. Johnson, H. Michael Petrassi
  • Patent number: 7279600
    Abstract: This invention provides estrogen receptor modulators having the structure: wherein R1 to R6 and R8 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: October 9, 2007
    Assignee: Wyeth
    Inventors: Richard Eric Mewshaw, Cuijian Yang
  • Patent number: 7253319
    Abstract: Compounds of the formula where the variables have the values described in the specification are antagonists of RAR? retinoid receptors.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: August 7, 2007
    Assignee: Allergan, Inc.
    Inventors: Kwok Yin Tsang, Santosh Sinha, Xiaoxia Liu, Smita Bhat, Roshantha A. Chandraratna
  • Patent number: 7169817
    Abstract: The present invention relates to biphenylyl derivatives, processes for their production, their uses and pharmaceutical compositions containing them. Compounds according to the present invention are based upon the chemical formula: wherein the substituents have the values mentioned herein.
    Type: Grant
    Filed: May 27, 2003
    Date of Patent: January 30, 2007
    Assignee: IRM LLC
    Inventors: Shifeng Pan, Nathanael S. Gray, Wenqui Gao, Klaus Hinterding, Sophie Lefebvre, Yuan Mi, Peter Nussbaumer, Wei Wang, Federic Zecri, Fan Yi, Lawrence Blas Perez, Kenneth Richad la Montagne, Peter Ettmayer
  • Patent number: 7157491
    Abstract: This invention provides estrogen receptor modulators having the structure where R1–R5 are as defined in the specification; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 13, 2004
    Date of Patent: January 2, 2007
    Assignee: Wyeth
    Inventors: Richard Eric Mewshaw, Stephen Todd Cohn
  • Patent number: 7115666
    Abstract: Disclosed are nitrone compounds and pharmaceutical compositions containing such compounds. The nitrone compounds have one to six additional carbons bridging between the nitrone functionality and the nitrone aryl ring. The disclosed compositions are useful as therapeutics for inflammation-related conditions and analgesia in mammals, such as arthritis, and for neuropathic pain and traumatic injuries such as traumatic brain injury and acute spinal cord injury.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: October 3, 2006
    Assignee: Renovis, Inc.
    Inventors: M. Amin Khan, Ravindra B. Upasani, Paul L. Wood
  • Patent number: 6998419
    Abstract: Disclosed are 3,4,5-trisubstituted aryl nitrone compoundsd and pharmaceutical compositions containing such compounds. The 3,4,5-trisubstituted aryl nitrone compounds have formula (I); where R1–R4 are as defined in the specification. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.
    Type: Grant
    Filed: January 12, 2004
    Date of Patent: February 14, 2006
    Assignee: Renovis, Inc.
    Inventors: L. David Waterbury, Allan L. Wilcox, John M. Carney, Farah Mavandadi, Albert Danielzadeh
  • Patent number: 6949557
    Abstract: The invention relates to the use of novel anthracene based compounds for the inhibition or prevention of the growth or multiplication of cancer cells, and to therapeutic compositions containing such compounds. The invention relates more specifically to the use of hydroanthracene based compounds for the inhibition and/or prevention of cancer of the colon, pancreas, prostate, lung, larynx, ovary, breast, glioblastoma, oral cavity, endothelial cells and leukemias. The agents of the invention form a distinct class, distinct from the anthracene, anthrone or anthraquinone derivatives.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: September 27, 2005
    Assignee: Dabur Research Foundation
    Inventors: Asish Kumar Banerjee, Venkatachalam Sesha Giri, Rama Mukherjee, Kamal K. Kapoor, Gautam Desiraju, Manu Jaggi, Anu T. Singh, Sankar Kumar Dutta, Kalapatapu V. V. M. Sairam
  • Patent number: 6852889
    Abstract: The invention provides novel adamantane compounds having one of the following formulas: wherein: R1 and R3 are H, OH, alkyl, cycloalkyl, amino or aryl, and can be the same or different; R2 is H, NH2, alkyl, OH, COOH, amino, amide, or carbamate; R4-R8 are H, OH, NH2, alkyl, OH, COOH, ester, amino, amide, or alkyloxy, and can be the same or different; R9-R14 are H, alkyl, or phenyl, and can be the same or different; and wherein when any of R1-R8 is amino, the compounds are the free bases and their acid addition salts. The present invention also relates to compositions and methods for treating and/or preventing neurological and inflammatory disorders in a patient by administering a therapeutically effective amount of the compounds of formula (I), (II) or (III) and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 30, 2004
    Date of Patent: February 8, 2005
    Assignees: Panorama Research, Inc., NeuroMolecular, Inc.
    Inventors: Yuqiang Wang, James W. Larrick
  • Patent number: 6849570
    Abstract: The present invention relates to a process for the production of a titanium silicalite shaped body by: (a) forming a formable composition containing titanium silicalite, a binder and a pasting agent, so that the Curd curve of the formable composition has a plateau value in the range from 20 to 90 mm; (b) shaping the composition of step (a) to form a green body; (c) optionally drying and (d) calcining the green body, to a titanium silicalite shaped body obtainable by that process, and to the use of such titanium silicalite shaped bodies in the epoxidation of olefins or the ammoximation of ketones.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: February 1, 2005
    Assignee: Degussa AG
    Inventors: Steffen Hasenzahl, Ralf Jantke
  • Patent number: 6824954
    Abstract: A sulfonyloxime compound is provided which is represented by a general formula (1): wherein, R1 represents a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group; R2 represents an alkyl group, an aryl group, or a heteroaryl group; X represents a halogen atom; Y represents —R3, a —CO—R3 group, —COO—R3 group, —CONR3R4 group, —S—R3 group, —SO—R3 group, —SO2—R3 group, a —CN group or a —NO2 group, and R3 and R4 within the Y group each represent a hydrogen atom, an alkyl group, an aryl group, or a heteroaryl group, although any two of R1, R2 and R3 may also be bonded together to form a cyclic structure, and furthermore dimers of a compound represented by the general formula (1) in which R1, R2 or Y groups from separate molecules are bonded together to form a single bivalent group, are also possible.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: November 30, 2004
    Assignee: JSR Corporation
    Inventors: Eiji Yoneda, Tatsuya Toneri, Yong Wang, Tsutomu Shimokawa